Skip to main content
OpenTrials
Completed

NCT Number: NCT03315858

NFAT-regulated Gene Expression After Tacrolimus

Aim of the study is measurement of NFAT-RGE (IL-2 (interleukin-2), IFN-γ (interferon-gamma), GM-CSF (granulocyte monocyte colony stimulating factor)) after tacrolimus (TAC) in de-novo immunosuppressed patients after liver transplantation (LT), to test the hypothesis that in de-novo TAC patients receiving mycophenolate mofetil (MMF) and steroids after LT there is an inverse correlation of NFAT-RGE and TAC peak levels at 1.5 hours after TAC intake.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Medical University of Graz, Klin. Abteilung für Transplantationschirurgie

Graz, 8036, Austria

About this study

The trial will be conducted as a prospective, longitudinal study. The study is a single-centre study performed at the Medical University of Graz, Department of Surgery, Division of Transplant Surgery and the Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz.

All the patients on the LT wailting list at the Division of Transplant Surgery, Medical University of Graz are screened according to both inclusion and exclusion criteria. The study period is 1 year. One NFAT-RGE baseline measurement is performed directly before LT; NFAT-RGE-measurements after LT are performed at clearly defined timepoints.

Study population. As a pilot trial this study comprises of 15 patients who will undergo LT

Objectives:

  • To test the hypothesis that in de-novo TAC patients receiving mycophenolate mofetil (MMF) and steroids after LT there is an inverse correlation of NFAT-RGE and TAC peak levels at 1.5 hours after TAC intake
  • To correlate both NFAT-RGE and TAC (trough and peak) levels with rejection episodes and TAC side effects

Approach:

NFAT-RGE is determined in 15 patients just before LT, and after LT after 1 day, 1 week, 2 weeks, and after 1, 6 and 12 months.

Methods. Heparinized peripheral blood is stimulated with 1 ml of complete Roswell Park Memorial Institute (RPMI) 1640 medium containing 100 ng/ml phorbol 12-myristate 13-acetate (PMA) and 5 mcg/ml ionomycin (Sigma-Aldrich Corp., St.Louis, MO, USA) for 3 hours at 37°C. Following ex vivo immune activation, after red cell lysis with ACK buffer (0.15 M NH4CL, 1.0 mM KHCO3), leukocytes are lysed with 400 mcl of MagNA-Pure lysis buffer supplemented with an additional 1% (W/v) of dithiothritol (RAS, Mannheim, Germany), and the sample is frozen at -70°C. After thawing, mRNA is isolated with the RNA Blood mini Kit (Quiagen) device using the mRNA standard protocol for cells. RNA is reverse transcribed using SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen, life technologies). The 3 NFAT-regulated genes (IFN-γ, IL-2, GM-CSF) were identified as suitable genes for this essay from previous studies [18, 26]. Target mRNA sequences of IFN- γ, IL-2, GM-CSF and 3 reference genes are amplified using commercially available PrimePCR ddPCR Gene Expression Probe Assays (Biorad) by digital PCR (Biorad).

The RGE after TAC intake is calculated as cpeak/c0x100, where c0 is the adjusted number of transcripts at the TAC predose level and cpeak is the number of transcripts 1.5 (c1.5) hours after drug intake.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients > 18 years of age
  • Liver transplantation
  • Informed consent

Exclusion criteria

  • Patients < 18 of years
  • Patients taking actively part in a different interventional trial

Treatment and study plan

Primary outcomes

  1. correlation of NFAT-RGE and TAC peak levels

    Time frame: 1 year

    Calculation: cpeak/c0x100

Secondary outcomes

  1. correlation of both NFAT-RGE and TAC (trough and peak) levels with rejection episodes and TAC side effects

    Time frame: 1 year

    Calculation: cpeak/c0x100

Sponsors and collaborators

Lead sponsor

Medical University of Graz

Other

Registry information

Official study title

NFAT (Nuclear Factor of Activated T-cells)-Regulated Gene Expression After Tacrolimus -the Basis for Future Tailored Immunosuppression-

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
Oct 20, 2017
Registry last updated
Feb 3, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.